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hypertrophy was absent (growth index: 5 * 4%, n.s.). In the mesenteric
artery the increased meditilumen ratio was also observed, but involved
hypertrophic remodeling (growth index: 32 + 10%, p < 0.05). The ETA-
reeeptor antagonist LU135252 prevented the structural changes in both
vascular beds (p <0.05 vs salt-treated DS rats). The mediahmen ratio was
significantly correlated with systolic blood pressure in basilar (r = 0.53, p
<0.01, linear regression) and mesenteric arteries (r = 0.79, p < 0.0001).
LU135252 had noeffectin the normotensive DR rats. These findings suggest
that the long-term pressor effect of salt administration is mediated, in part, by
the action of endogenous ET,acting on ETA-receptors.Thus, selective ETA-
receptor antagonists may be therapeutically useful to lower arterial pressure
and improve vascular remodeling of resistance arteries in salt sensitive
individuals.
1027-177 Poor Regression in Hypertensive Alcoholic Rsts
on Lisinopril Therspy
V.B. Patel 1, G.S. Sandhu, J.M. Corbett2, M.J. Dunn2, P.J. Richardson3,
V.R. Preedy’. 1Department of Clinica/Biocfremistry King’s Co//age
Hospita/, London, UK, 3 Department of Cardiology King’s College Hospital,
London, UK, 2 Department of CafcfiothoracicSurgery Harefie/d Hospita/,
Middlesex, UK
Hypertensive subjeets who are also alcoholics are poorly managed. The
mechanisms for this are unknown, but we hypothesised an interaction at
the contractile-protein level. We tested this theory in the following groups;
(a) SHR control, (b) SHR + alcohol, (c) SHR control + Iisinopril, (d) SHR +
alcohol + Iisinopril. Alcohol was administered for 6 weeks and constituted
35% of total calories. Lisinopril was given”in the diet at a doae of 5 mg/kg
Imfy weight. After 6 weeks the myofibrillary frsctions were isolated by sub-
cellular fractionation. The myofibrillary fraction of the heart was analysed by
SDS-PAGE and produced 9 distinct contractile proteins. The results showed
reduced amounts of myosin heavy chain (–20%, P < 0.01), myosin light
chain (–24%, P c 0.01), and troponin (–21%, P < 0.01) in hypertensive
alcoholic rats in comparison to control hypertensive rats. Hypertensive rats
on Iiainopril therapy showed reductions in left ventricle weight (–36%, P <
0.001) and tisaue protein composition in comparison to control hypertensive
rats. However, animals on concomitant alcohol and Iiainopril had significantly
higher wet weights (+20%, P < 0.001) and myofibrillar protein content (+24~o,
P < 0.01) than hypetiensives on Iisinopril. Individual contractile proteins were
aLsohigher but failed to attain significance. In conclusion, hypertensive alco-
holic rats have impaired contractile composition. Alcoholic rata on Iisinopril
therapy show poor regression of contractile apparatus.
11027-1781 MyocmfialTisSueConcentrStionsOf
Amiodarone end Deeethylamiodarone After
Chronic Treatment: Correlation With Local
Action Potential Duration
M.R. Franz, S. Behrens, C. Li. VeteransAdministration and Georgetown
Urriversi~, Washington, DC, USA
To better understand the pharmacodynamic and electrophysiologic proper-
ties of amioderone (A), we determined the relationship between chronic A
treatment, myoeardial tissue concentration (TC) of A and its metabolizede-
sethylamiodarone (DEA), and the correlation between TC of A and DEA with
local myocsrdial depolarization effects. Six hearts of rabbits loaded with A
for 6 weeks (50 mg/kgfday) were isolated and Langendoti-perfused while
monophasic action potential durations (MAPDs) were measured simultane-
ously at 10 sites of both ventricles during regular pacing at 600 msec cycle
length. Each MAP recording site was marked and tissue excised for subse-
quent analysis of A and DEA TC using highdensity liquid chromatography.
A and DEA TC were widely disparate within a single heart and between
different hearts (range 1.2 to 35.6 wglg). Despite this variance, A and DEA
TC consistently were high,estwithin epicardial (11.2 * 7.6 @g), lowest in
midmyocsvdial (3.9 +2.3), and intermediate inendocardial tissue (4.6 + 3.5).
MAPD also varied widely within individual and all hearts, ranging from 133
to 210 msec despite constant 600 resee pacing. When the entire range of A
and DEA TC from all 6 hearts was correlated with MAPD, a highly significant
correlation was found between MAPD and DEA (r = 0.63, p < 0.0001) but
not between MAPD and A (r = 0.30, p = 0.04).
Conclusions: 1) Six-wwks of A treatment result in widely disparate TC of
both A and DEA within ventricular myooardium of a single hearts and within
different hearts. 2) DEA but not A is responsible for significant increase
in depolarization time. 3) MAPD distribution reflects thie dispersed TC and
accurately identifies the local depolarizationprolonging effect of DEA. 4) The
extremely heterogenoue myocardial tissue uptake of A and DEA may help
explain deficiencies in Atreatment effectiveness.
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G.M.C. Rosano, S.L. Chierchia, GL. Morgagni, M. Gabriele, F. Leonardo,
P.M.Sarrel, P.Collins. Dept. of Cardiology kvituto Scientific H San
Raffae/e, fvfi/ano-f30rna,/ta/y Nationa/ Heart& Lung /nstitute, London, UK
Estrogens have a protective effect upon the cardiovascular system and
Estradiol 17B (E) has been shown to have vasoactive and anti-ischemic
properties, However, little is known on the cardiovascular effect of adding
progestogens to estrogens in order to reduce the likelihood of the latter to
facilitate uterine cancer, The aim of this randomized double-blind cross-over
study was to evaluate the effect of adjunctive therapy with Progesterone (P,
45 m~daily) ormedroxyprogesterone (MPA, 10 mgldaily) to E upon exercise-
induced myoeardial ischemia in 18 postmenopausal women with CAD. Two
pts were withdrawn during the MPA phase because of unstable angina.
Compared to baseline E alone increased time to 1 mm ST$ (325 + 156 vs
257 + 143 sac, p < 0.01). In 5 pts in whom the exercise test was negative
after E + P the test become positive during E + MPA (p < 0.01). Compared
to baseline E + P increased both time to 1 mm STJ.and exercise time (416
* 156 vs 257 + 143 see, p c 0.01 end 435 + 195 vs 365 + 198 see, p <
0.05, respectively). By contrast, no difference was found between baseline
and E + MPA in either time to 1 mm ST+ or exercise time (298 l 146 vs 257
+ 143 see, p = NS and 411 + 202 vs 365 + 198 see, p = NS, respectively).
In conclusion MPA but not natural P reverses the effect of chronic therapy
with E upon exercise-induced myocardial ischemia. The progestogen to use
in adjunct to E must be carefully chosen when menopausal pts with CAD are
prescribed hormone replacement therapy.
-[ Safety, Pfrarmacokinetics, andlmmunogenicity
of Intravenous Administration of h5G1.1-scFv in
Humana
J.C.K. Fitch, J,A. Elefteriades, L.A. Matis, M.J. Evans, H.M. Rinder,
S.A. Rollins, B.L. Alford, R.L. Hinea. Ya/eUniversity Schoo/ of Medicine and
Alexion Pharmaceuticals, Inc., New Haven, CT USA
Complement activation during cardiopulmonary bypaas (CPB) eontributea to
a systemic inflammato~ response associated with excessive bleeding, and
pulmonaty and cardiac dysfunction. This is the first human clinical report of
the safety, pharmacokinetice, and immunogenicity of a humanized single-
chain monoclinal antibody, designated h5Gl .l-ecFv, which blocks the gen-
eration of C5a and C5b-9. The antibody is being evaluated in two Phase I
studies. The initial study was designed as a single-blind, placebo-controlled,
ascending-dose study of h5Gl .I-scFv in healthy male volunteers. Subjects
received a single dose of h5G1.1-scFvor placebo administered intravenously
at one of four dose levels (0.2, 0.5, 1.0 or 2.0 mg/kg). In contrast to the very
rapid clearance normally observed following injection of single chain antibod-
ies, the h5Gl .I-scFv displayed a serum half life of greater than 10 hours,
presumably secondary to its vety high affinity binding to the larger C5 protein
in plasma. Prolonged systemic inhibition of the complement caacade was
achieved in a dose dependent manner. At the higheat dose, complement
dependent hemolyfic activity was completely inhibited for4 hours and signif-
icant inhibition was obsetved for greater than 12 hours. The follow-on atudy
was designed as a placebo-controlled, open-label, ascending dose study in
CABG patients. A total of 4 doses plus placetm were tested with 3 cohorts
in each dose. Safety date was assessed based on the WHO Recommenda-
tions. Assays were done to assess the extent of complement, leukocyte and
platelet activation aa well as fibrinolysis. Administration of h5G1.1-scFv up
to single intravenous dose of 2 mg/kg is safe and well tolerated. Based on
these preliminary biological effects, we propose that the use of an anti-C5
antibody will significantly reduce the impact of complement-mediated injuries
sustained during CPB. Further clinical studies will be carried out to delineate
the potential efficacy of an anti-C5 antibody.
